

### Announcement Summary

Entity name STARPHARMA HOLDINGS LIMITED

### **Announcement Type**

New announcement

Date of this announcement Wednesday September 30, 2020

### The Proposed issue is:

☑ An offer of securities under a securities purchase plan
 ☑ A placement or other type of issue

Total number of +securities proposed to be issued for an offer of securities under a securities purchase plan

ASX +security code	+Security description	Maximum Number of +securities to be issued
SPL	ORDINARY FULLY PAID	3,333,333

### +Record date

Tuesday September 29, 2020

# Offer closing date

Tuesday October 27, 2020

### +Issue date

Wednesday November 4, 2020

Total number of +securities proposed to be issued for a placement or other type of issue

ASX +security code	+Security description	Maximum Number of +securities to be issued
SPL	ORDINARY FULLY PAID	30,000,000

### Proposed +issue date

Tuesday October 6, 2020

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

## 1.1 Name of +Entity

## STARPHARMA HOLDINGS LIMITED

We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.

**1.2 Registered Number Type** 

ACN

**Registration Number** 

078532180

1.3 ASX issuer code

SPL

# 1.4 The announcement is

New announcement

# 1.5 Date of this announcement

Wednesday September 30, 2020

### 1.6 The Proposed issue is:

☑ An offer of +securities under a +securities purchase plan
 ☑ A placement or other type of issue



Part 4 - Details of proposed offer under securities purchase plan

Part 4A - Conditions

4A.1 - Are any of the following approvals required for the offer of +securities under the +securities purchase plan issue to be unconditional?

- +Security holder approval
- Court approval
- Lodgement of court order with +ASIC
- ACCC approval
- FIRB approval
- Another approval/condition external to the entity

🕑 No

Part 4B - Offer details

Class or classes of +securities that will participate in the proposed issue and class or classes of +securities proposed to be issued

ASX +security code and description

SPL : ORDINARY FULLY PAID

Will the proposed issue of this +security include an offer of attaching +securities? ☑ No

Details of +securities proposed to be issued

ASX +security code and description

SPL : ORDINARY FULLY PAID

Maximum total number of those +securities that could be issued if all offers under the +securities purchase plan are accepted

3,333,333

Will the offer be conditional on applications for a minimum number of +securities being received or a minimum amount being raised (i.e. a minimum subscription condition)? ⓒ No



Is the minimum acceptance unit based or dollar based?  $\ensuremath{\mathfrak{S}}$  Dollar based (\$)

Please enter the minimum acceptance value

\$1,500

Is the maximum acceptance unit based or dollar based? ☑ Dollar based (\$)

Please enter the maximum acceptance value

\$ 30,000

### Describe all the applicable parcels available for this offer in number of securities or dollar value

\$1,500, \$3,000, \$5,000, \$7,500, \$10,000, \$15,000, \$20,000, \$25,000, \$30,000

### Offer price details

Has the offer price been determ ℭ Yes	ined?
In what currency will the offer	What is the offer price per
be made?	+security?

AUD - Australian Dollar AUD 1.50000

### **Oversubscription & Scale back details**

Will a scale back be applied if the offer is over-subscribed? ☑ Yes

### Describe the scale back arrangements

Starpharma may consider a Shareholder's pro-rata allocation, together with considering minimum allocations. If a scale back produces a fractional number of SPP Shares when applied to the parcel, the number of SPP Shares allotted will be rounded down to the nearest whole number of SPP shares.

# Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?

🕑 Yes

Part 4C - Timetable



### 4C.1 Date of announcement of +security purchase plan

Wednesday September 30, 2020

# 4C.2 +Record date

Tuesday September 29, 2020

# 4C.3 Date on which offer documents will be made available to investors

Wednesday October 7, 2020

# 4C.4 Offer open date

Wednesday October 7, 2020

# 4C.5 Offer closing date

Tuesday October 27, 2020

# 4C.6 Announcement of results

Thursday October 29, 2020

# 4C.7 +Issue date

Wednesday November 4, 2020

Part 4D - Listing Rule requirements

Part 4E - Fees and expenses

4E.1 Will there be a lead manager or broker to the proposed offer?  $\ensuremath{\mathfrak{C}}$  No



4E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed offer N/A

## Part 4F - Further Information

4F.01 The purpose(s) for which the entity intends to use the cash raised by the proposed issue

Additional working capital

**4F.1 Will the entity be changing its dividend/distribution policy if the proposed offer is successful?** ☑ No

**4F.2 Countries in which the entity has +security holders who will not be eligible to accept the proposed offer** Only shareholders in Australia and New Zealand are eligible to participate in the SPP

4F.3 URL on the entity's website where investors can download information about the proposed offer

https://starpharma.com/asx announcements

4F.4 Any other information the entity wishes to provide about the proposed offer



Part 7 - Details of proposed placement or other issue

Part 7A - Conditions

7A.1 - Are any of the following approvals required for the placement or other type of issue?

- +Security holder approval
- **Court approval**
- Lodgement of court order with +ASIC
- ACCC approval
- **FIRB** approval
- Another approval/condition external to the entity

C No

TOT

Part 7B - Issue details

Is the proposed security a 'New class' (+securities in a class that is not yet quoted or recorded by ASX) or an 'Existing class' (additional securities in a class that is already quoted or recorded by ASX)? C Existing class

Will the proposed issue of this +security include an offer of attaching +securities? 🕑 No

### Number of +securities proposed to be issued

 

 Details of +securities proposed to be issued

 ASX +security code and description

 SPL : ORDINARY FULLY PAID

 Number of +securities proposed to

 30,000,000

 Offer price details

 Are the +securities proposed to be

 '-toration?

Are the +securities proposed to be issued being issued for a cash C Yes

> In what currency is the cash consideration being paid?

What is the issue price per +security? AUD 1.50000

AUD - Australian Dollar

Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class? C Yes



Part 7C - Timetable

7C.1 Proposed +issue date

Tuesday October 6, 2020

Part 7D - Listing Rule requirements

7D.1 Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? ⓒ No

7D.1b (i) How many +securities are proposed to be issued without security holder approval using the entity's 15% placement capacity under listing rule 7.1?

30,000,000

7D.2 Is a party referred to in listing rule 10.11 participating in the proposed issue?  $\textcircled{\sc No}$ 

**7D.3 Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules?** So

7D.4 Will any of the +securities to be issued be subject to +voluntary escrow? ☑ No

Part 7E - Fees and expenses

7E.1a Who is the lead manager/broker?

Bell Potter Securities Limited

7E.1b What fee, commission or other consideration is payable to them for acting as lead manager/broker?

Management Fee 1% Selling Fee 2.75%



## 7E.2 Is the proposed issue to be underwritten? 🕑 No

7E.4 Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue N/A

## 7F.01 The purpose(s) for which the entity is issuing the securities

Additional working capital

7F.1 Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? 🕑 No

7F.2 Any other information the entity wishes to provide about the proposed issue